Chiasma (CHMA) Stock Analysis

What Chiasma does

Chiasma, Inc. is a biopharmaceutical company in the advanced stages of clinical development, specializing in oral drug formulations. The company utilizes its Transient Permeability Enhancer (TPE) technology platform to develop treatments for rare and serious chronic conditions on a global scale. A key product in its pipeline is MYCAPSSA, an oral octreotide capsule currently in Phase III clinical trials. MYCAPSSA is intended for adult patients diagnosed with acromegaly, a disorder marked by the overproduction of growth hormone in the body. Founded in 2001, Chiasma, Inc. is headquartered in Needham, Massachusetts.

Key metrics

ETFs linked to CHMA

Broad-market and Healthcare sector ETFs an investor holding Chiasma is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how CHMA fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Chiasma?

Chiasma trades under the ticker CHMA on NASDAQ.

Which exchange is CHMA listed on?

CHMA is listed on NASDAQ.

What sector does Chiasma operate in?

Chiasma is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze CHMA in a portfolio?

PortView shows CHMA's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.